积极与非积极静脉水化治疗急性胰腺炎临床结局比较:系统评价与Meta分析
该研究遵循PRISMA指南,系统检索PubMed、Embase和Cochrane Library(截至2022年11月23日)的随机对照试验,最终纳入9项RCT共953例急性胰腺炎患者,采用随机效应模型分别对重症和非重症AP进行Meta分析。主要结局为全因死亡率,次要结局包括液体相关并发症、临床改善和48小时内APACHE II评分。结果显示,与非积极静脉水化相比,积极静脉水化显著增加重症AP死亡风险(合并RR 2.45,95%CI 1.37-4.40),非重症AP结果不确定(合并RR 2.26,95%CI 0.54-9.44);积极静脉水化显著增加重症(合并RR 2.22,95%CI 1.36-3.63)和非重症(合并RR 3.25,95%CI 1.53-6.93)AP的液体相关并发症风险,并导致重症AP的APACHE II评分更差(合并均数差3.31,95%CI 1.79-4.84),非重症AP临床改善可能性未增加(合并RR 1.20,95%CI 0.63-2.29)。仅纳入初始液体复苏后采用目标导向液体治疗的RCT进行敏感性分析,结果一致。
要点
- 重症急性胰腺炎中,积极静脉水化较非积极水化显著增加死亡风险(合并RR 2.45,95%CI 1.37-4.40)。
- 积极静脉水化显著增加液体相关并发症风险:重症AP合并RR 2.22(95%CI 1.36-3.63),非重症AP合并RR 3.25(95%CI 1.53-6.93)。
- 重症AP中积极静脉水化组APACHE II评分更差(合并均数差3.31,95%CI 1.79-4.84)。
- 非重症AP中积极静脉水化未增加临床改善可能性(合并RR 1.20,95%CI 0.63-2.29),死亡风险结果不确定(合并RR 2.26,95%CI 0.54-9.44)。
- 仅纳入初始液体复苏后采用目标导向液体治疗的RCT进行敏感性分析,结果一致。
适用人群与场景
- 急性胰腺炎(AP)患者,包括重症AP和非重症AP。
处置流程与药物剂量
- 作者建议:对于急性胰腺炎,建议采用更保守的静脉液体复苏方案。
研究设计与关键结果
- 系统评价与Meta分析,纳入9项RCT共953例急性胰腺炎患者,比较积极与非积极静脉水化。
- 主要结局:重症AP中积极水化较非积极水化显著增加死亡风险(合并RR 2.45,95%CI 1.37-4.40);非重症AP结果不确定(合并RR 2.26,95%CI 0.54-9.44)。
- 液体相关并发症:重症AP合并RR 2.22(95%CI 1.36-3.63),非重症AP合并RR 3.25(95%CI 1.53-6.93),积极水化均显著增加风险。
- APACHE II评分:重症AP中积极水化组更差(合并均数差3.31,95%CI 1.79-4.84)。
- 临床改善:非重症AP中积极水化未增加临床改善可能性(合并RR 1.20,95%CI 0.63-2.29)。
- 敏感性分析:仅纳入初始液体复苏后采用目标导向液体治疗的RCT,结果一致。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入9项随机对照试验(RCT),共953例参与者。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议:对于急性胰腺炎,建议采用更保守的静脉液体复苏方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current practice guidelines for optimal infusion rates during early intravenous hydration in patients with acute pancreatitis (AP) remain inconsistent. This systematic review and meta-analysis aimed to compare treatment outcomes between aggressive and non-aggressive intravenous hydration in severe and non-severe AP.
METHODS: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We systematically searched PubMed, Embase and Cochrane Library for randomized controlled trials (RCTs) on November 23, 2022, and hand-searched the reference lists of included RCTs, relevant review articles and clinical guidelines. We included RCTs that compared clinical outcomes from aggressive and non-aggressive intravenous hydration in AP. Meta-analysis was performed using a random-effects model for participants with severe AP and non-severe AP. Our primary outcome was all-cause mortality, and several secondary outcomes included fluid-related complications, clinical improvement and APACHE II scores within 48 h.
RESULTS: We included a total of 9 RCTs with 953 participants. The meta-analysis indicated that, compared to non-aggressive intravenous hydration, aggressive intravenous hydration significantly increased mortality risk in severe AP (pooled RR: 2.45, 95% CI: 1.37, 4.40), while the result in non-severe AP was inconclusive (pooled RR: 2.26, 95% CI: 0.54, 9.44). However, aggressive intravenous hydration significantly increased fluid-related complication risk in both severe (pooled RR: 2.22, 95% CI 1.36, 3.63) and non-severe AP (pooled RR: 3.25, 95% CI: 1.53, 6.93). The meta-analysis indicated worse APACHE II scores (pooled mean difference: 3.31, 95% CI: 1.79, 4.84) in severe AP, and no increased likelihood of clinical improvement (pooled RR:1.20, 95% CI: 0.63, 2.29) in non-severe AP. Sensitivity analyses including only RCTs with goal-directed fluid therapy after initial fluid resuscitation therapy yielded consistent results.
CONCLUSIONS: Aggressive intravenous hydration increased the mortality risk in severe AP, and fluid-related complication risk in both severe and non-severe AP. More conservative intravenous fluid resuscitation protocols for AP are suggested.
参考来源
- Li XW, Wang CH, Dai JW, et al. Comparison of clinical outcomes between aggressive and non-aggressive intravenous hydration for acute pancreatitis: a systematic review and meta-analysis. Crit Care. 2023. PMID: 36949459. doi:10.1186/s13054-023-04401-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。